GLP-2T and GLP-3R are multi-receptor incretin-based peptides used in receptor pharmacology research. GLP-2T is a dual GIP/GLP-1 receptor agonist, while GLP-3R adds a third target: the glucagon receptor.
| Property | GLP-2T | GLP-3R |
|---|---|---|
| Category | GIP/GLP-1 dual receptor agonist (twincretin) | GIP/GLP-1/glucagon triple receptor agonist ("triple G") |
| Mechanism of Action | Activates GIP and GLP-1 receptors; used to study dual incretin receptor signaling and cAMP responses | Adds glucagon receptor agonism to the dual incretin mechanism; used to study three-receptor signaling and receptor cross-talk in cell models |
| Molecular Weight | ~4,810 Da (39 amino acids) | ~4,731 Da (39-amino-acid backbone with C-20 fatty diacid) |
| Research Focus | GIP/GLP-1 receptor co-agonism assays | GIP/GLP-1/glucagon receptor tri-agonism assays |
| Receptor Target | GIP receptor + GLP-1 receptor | GIP receptor + GLP-1 receptor + glucagon receptor |
| Half-Life | ~5 days (C-20 fatty diacid, albumin binding) | ~6 days (fatty diacid modification, albumin binding) |
GLP-2T and GLP-3R represent successive generations of multi-receptor incretin pharmacology. GLP-2T pairs GIP and GLP-1 receptor agonism. GLP-3R extends the approach with glucagon receptor agonism. Both are lipidated 39-amino-acid peptides with multi-day half-lives, which is relevant to assay design and stability studies.
GLP-2T is a dual GIP/GLP-1 receptor agonist, while GLP-3R is a triple agonist that adds glucagon receptor activation. Both are lipidated 39-amino-acid peptides with albumin-binding modifications. The pair is used to compare two-receptor and three-receptor signaling in cell-based assays.
Disclaimer: All compounds referenced on this page are sold for research and laboratory use only. The comparisons presented are based on published scientific literature and are intended for educational and informational purposes. This content does not constitute medical advice. Researchers should consult primary literature and applicable regulations before designing study protocols.